海辰药业(300584.SZ)：公司注射用盐酸兰地洛尔被纳入国家医保目录

Core Viewpoint - Haicheng Pharmaceutical has successfully renewed the inclusion of its injectable Labetalol Hydrochloride (50mg) and has achieved the first-time inclusion of injectable Labetalol Hydrochloride (150mg) in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1] Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released a notification regarding the updated drug catalog for 2025 [1] - The successful renewal of the 50mg formulation indicates continued support for Haicheng Pharmaceutical's product line [1] - The first-time inclusion of the 150mg formulation expands the company's market access and potential revenue streams [1]